Sujal (@sujalsa) 's Twitter Profile
Sujal

@sujalsa

CEO, CymaBay Therapeutics

ID: 2413962204

calendar_today27-03-2014 09:21:01

29 Tweet

25 Followers

38 Following

CymaBay Therapeutics (@cymabay) 's Twitter Profile Photo

It’s officially the first day of #PBCAwarenessMonth! CymaBay is proud to support the PBCers Organization and their ongoing efforts to spread awareness for this rare and chronic liver disease. To learn more, visit pbcers.org #PBC #RareDisease #LiverDisease #PBCAwareness

It’s officially the first day of #PBCAwarenessMonth!
CymaBay is proud to support the <a href="/PBCers/">PBCers Organization</a> and their ongoing efforts to spread awareness for this rare and chronic liver disease. To learn more, visit pbcers.org
#PBC #RareDisease #LiverDisease #PBCAwareness
Peter Kolchinsky (@peterkolchinsky) 's Twitter Profile Photo

Dear Lawmakers President Donald J. Trump Ron Wyden Nancy Pelosi Hundreds of us biotech investors, innovators, patient advocates, & NIH academics representing >40k US jobs, >600 drugs in trials, & >$200B invested propose solutions to affordability that preserve R&D. 1/ nopatientleftbehind.docsend.com/view/a6bxibzxy…

CymaBay Therapeutics (@cymabay) 's Twitter Profile Photo

On International PBC Awareness Day, CymaBay wears GREEN! Today we celebrate International PBC Day to raise awareness for PBC and the impact it has on patients’ lives. To learn more and to get involved, follow PBC Foundation and visit pbcfoundation.org.uk #PBCday2021 #PBC

On International PBC Awareness Day, CymaBay wears GREEN! Today we celebrate International PBC Day to raise awareness for PBC and the impact it has on patients’ lives. 
To learn more and to get involved, follow <a href="/PBCFoundation/">PBC Foundation</a> and visit pbcfoundation.org.uk
#PBCday2021 #PBC
CymaBay Therapeutics (@cymabay) 's Twitter Profile Photo

“During PBC Awareness Month, I would like to underscore CymaBay’s commitment to helping find an effective and tolerable treatment for patients living with PBC through our ongoing research of seladelpar.”- Sujal Shah, President and CEO of CymaBay Therapeutics. #PBCAwarenessMonth

“During PBC Awareness Month, I would like to underscore CymaBay’s commitment to helping find an effective and tolerable treatment for patients living with PBC through our ongoing research of seladelpar.”- Sujal Shah, President and CEO of CymaBay Therapeutics.
#PBCAwarenessMonth
CymaBay Therapeutics (@cymabay) 's Twitter Profile Photo

We are proud to announce CymaBay’s upcoming presentations on studies of seladelpar at The Liver Meeting® AASLD. The meeting will take place Nov. 12-15. For more information, click on the link below: ir.cymabay.com/press-releases… #TLMdX #AASLD #LiverDisease

We are proud to announce CymaBay’s upcoming presentations on studies of seladelpar at The Liver Meeting® <a href="/AASLDtweets/">AASLD</a>. The meeting will take place Nov. 12-15.
For more information, click on the link below:
ir.cymabay.com/press-releases…
#TLMdX #AASLD #LiverDisease
CymaBay Therapeutics (@cymabay) 's Twitter Profile Photo

We're excited to share the data from Cynthia Levy, MD’s presentation from this year’s #TLMdX mtg with AASLD. The presentation highlighted the effects of 3 months of seladelpar treatment in patients with cirrhosis and portal hypertension due to #PBC. ir.cymabay.com/press-releases…

We're excited to share the data from <a href="/DrCynthiaLevy/">Cynthia Levy, MD</a>’s presentation from this year’s #TLMdX mtg with <a href="/AASLDtweets/">AASLD</a>. The presentation highlighted the effects of 3 months of seladelpar treatment in patients with cirrhosis and portal hypertension due to #PBC. ir.cymabay.com/press-releases…
CymaBay Therapeutics (@cymabay) 's Twitter Profile Photo

We're proud to announce our last patient has been enrolled in the Phase 3 RESPONSE trial. Thank you to all the patients, investigators & sites for your contributions & dedication to researching addt'l treatment options for patients w/ #PBC. Learn more: ir.cymabay.com/press-releases…

We're proud to announce our last patient has been enrolled in the Phase 3 RESPONSE trial. Thank you to all the patients, investigators &amp; sites for your contributions &amp; dedication to researching addt'l treatment options for patients w/ #PBC. Learn more: ir.cymabay.com/press-releases…
Prep Baseball Scouting (@pbtscouting) 's Twitter Profile Photo

INF Jayden Patel (Lake Park, 2024; @PBRIllinois) goes the other way for a pair of hits early on. 6-foot-2, 170-pounds Posted a max EV of 96 mph at the #OHareID this preseason. #PBRTILOpen | @PBR_Uncommitted

Jig Patel (@jig0718) 's Twitter Profile Photo

Big win for Lake Park and a big game for Jayden 3-4, 6 RBIs including a grand slam off the scoreboard! ⁦@LPBaseball2023⁩ ⁦Schaumburg Seminoles⁩⁩ ⁦Jayden Patel⁩ ⁦@pbrtscouting⁩ ⁦@PBR_Uncommitted⁩

Jayden Patel (@jaydenpatel23) 's Twitter Profile Photo

Grand Slam I had from the Phil Lawler tournament Stats- avg- .400 rbi-11 0 strike outs in 17 PA SLG- .933 (1 double 2 Triples 1 homerun) @LPBaseball2023

Jayden Patel (@jaydenpatel23) 's Twitter Profile Photo

Had a fun time in Indiana for the last tournament of the summer taking second place in the Circle City Cup! Here are some stats at Grand Park: avg- .500 (6/12) obp- .625 slg- .667 ops- 1.292 HBP-3 IBB-1 @LPBaseball2023 Schaumburg Seminoles Baseball_Uncommitted UncommittedPlayersUSA

CymaBay Therapeutics (@cymabay) 's Twitter Profile Photo

#NEWS: We're announcing the initiation of the IDEAL study, a phase 3, randomized, placebo-controlled study of our investigational treatment in patients with #PrimaryBiliaryCholangitis. Read the latest on our news page: bit.ly/3Ywfoaj

#NEWS: We're announcing the initiation of the IDEAL study, a phase 3, randomized, placebo-controlled study of our investigational treatment in patients with #PrimaryBiliaryCholangitis. 

Read the latest on our news page: bit.ly/3Ywfoaj
CymaBay Therapeutics (@cymabay) 's Twitter Profile Photo

#NEWS: We've announced positive topline results from our Pivotal Phase 3 RESPONSE study, evaluating the safety and efficacy of our investigational treatment for patients with #PrimaryBiliaryCholangitis. Read the latest on our news page: bit.ly/3LQNDUX

#NEWS: We've announced positive topline results from our Pivotal Phase 3 RESPONSE study, evaluating the safety and efficacy of our investigational treatment for patients with #PrimaryBiliaryCholangitis.  

Read the latest on our news page: bit.ly/3LQNDUX
CymaBay Therapeutics (@cymabay) 's Twitter Profile Photo

#NEWS: The FDA has granted a revised #BreakthroughTherapyDesignation for our investigational therapy for the treatment of #PrimaryBiliaryCholangitis (PBC) to include pruritus in adults without cirrhosis or with compensated cirrhosis. For more, visit: bit.ly/3MbzKkd

#NEWS: The FDA has granted a revised #BreakthroughTherapyDesignation for our investigational therapy for the treatment of #PrimaryBiliaryCholangitis (PBC) to include pruritus in adults without cirrhosis or with compensated cirrhosis. For more, visit: bit.ly/3MbzKkd
CymaBay Therapeutics (@cymabay) 's Twitter Profile Photo

We had the opportunity to welcome patients with #PrimaryBiliaryCholangitis to speak about their journey. Hearing from patients affirms our commitment to help those with liver and other chronic diseases feel better and lead healthier, richer lives. #LiverAwarenessMonth

We had the opportunity to welcome patients with #PrimaryBiliaryCholangitis to speak about their journey. Hearing from patients affirms our commitment to help those with liver and other chronic diseases feel better and lead healthier, richer lives. #LiverAwarenessMonth